NCT04776044 (RESPIRE) is a Phase 2 clinical trial of ATR-002 in COVID-19, sponsored by Atriva Therapeutics GmbH.

Who is sponsoring NCT04776044?

NCT04776044 is sponsored by Atriva Therapeutics GmbH.

What drugs are being tested in NCT04776044?

Interventions in NCT04776044: ATR-002, Placebo.

Is NCT04776044 still recruiting?

NCT04776044 is currently terminated. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT04776044: RESPIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19

Terminated Phase 2 Last updated 22 September 2022

What this trial tests

Phase 2 trial testing ATR-002 in COVID-19 in 133 participants. Terminated before completion.

Timeline

12 April 2021

Primary endpoint
6 June 2022

9 August 2022

Quick facts

Lead sponsor	Atriva Therapeutics GmbH
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	133
Start date	12 April 2021
Primary completion	6 June 2022
Estimated completion	9 August 2022
Sites	40 locations across South Africa, Netherlands, Germany, Poland, Romania, Spain, India

Drugs / interventions tested

ATR-002 — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Atriva Therapeutics GmbH — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the safety and efficacy of ATR-002 (in addition to standard-of-care) for the treatment of COVID-19

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Monoclonal antibody therapies in the management of SARS-CoV-2 infection.
Miguez-Rey E, Choi D, Kim S, Yoon S, et al · · 2022 · cited 34× · PMID 35164631 · DOI 10.1080/13543784.2022.2030310
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Kumar S, Çalışkan DM, Janowski J, Faist A, et al · · 2021 · cited 24× · PMID 34659259 · DOI 10.3389/fimmu.2021.752227
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs.
Schreiber A, Ambrosy B, Planz O, Schloer S, et al · · 2022 · cited 23× · PMID 36145524 · DOI 10.3390/pharmaceutics14091776
Unveiling the role of host kinases at different steps of influenza A virus life cycle.
Dey S, Mondal A. · · 2024 · cited 21× · PMID 38174932 · DOI 10.1128/jvi.01192-23
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases.
Ludwig S, Pleschka S, Planz O. · · 2023 · cited 15× · PMID 36841033 · DOI 10.1016/j.coviro.2023.101304
Emerging small molecule antivirals may fit neatly into COVID-19 treatment.
Fenton C, Keam SJ. · · 2022 · cited 14× · PMID 35250258 · DOI 10.1007/s40267-022-00897-8
Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.
Rohde G, Stenglein S, Prozesky H, Manudhane G, et al · · 2023 · cited 12× · PMID 38106555 · DOI 10.1016/j.eclinm.2023.102237
MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant <i>Staphylococcus aureus</i> infection.
De M, Serpa G, Zuiker E, Hisert KB, et al · · 2024 · cited 10× · PMID 38352056 · DOI 10.3389/fcimb.2024.1275940

Verify or expand the search:

Other trials of ATR-002

Trials testing the same drug.

NCT05555823 — Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Za · Phase 1 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Atriva Therapeutics GmbH trials

Trials by the same sponsor.

NCT05555823 — Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Za · Phase 1 · completed
NCT04385420 — Phase 1 Study of ATR-002 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04776044 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atriva Therapeutics GmbH
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing